## MOH: Molina Healthcare, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 10.5% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($171.36)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Is Molina Healthcare The Next GEICO? Michael Burry Feels It's A ‘Special One’**
- Source: Asianet Newsable | 20260103T190813 | Bullish | Relevance: 100%
- Hedge fund manager Michael Burry — well-known for his prescient short positions — recently offered encouraging comments about the health insurer Molina Healthcare, Inc. (MOH). He likened Molina to an early-stage GEICO, arguing it is undervalued and offers a clearer path to long-term earnings growth than many large-cap peers. Burry believes Molina is a "special one" in the insurance industry, despite its recent struggles and analyst skepticism.

**2. Molina Healthcare (MOH) director awarded 317 shares for quarterly service**
- Source: Stock Titan | 20260103T020838 | Neutral | Relevance: 100%
- Molina Healthcare, Inc. reported that a director received 317 shares of common stock on January 1, 2026, as a grant for board service under the company’s 2025 Equity Incentive Plan. This award represents a quarterly portion of $55,000 from an annual equity value of $220,000, determined by the closing stock price on December 31, 2025. Following this transaction, the director directly owns 3,742 shares of Molina Healthcare common stock.

**3. Barclays Raises Price Target for Molina Healthcare (MOH) | MOH S**
- Source: GuruFocus | 20260105T151920 | Neutral | Relevance: 100%
- Barclays has maintained its "Underweight" rating on Molina Healthcare (MOH) but increased its price target from $144 to $164, a 13.89% adjustment. This move reflects recent analyst adjustments, where some firms have lowered price targets while others have maintained ratings. Molina Healthcare, a provider of medical insurance plans predominantly through Medicaid, faces varied analyst perspectives on its market position and future performance.

**4. Merit Financial Group LLC Buys 8,721 Shares of Molina Healthcare, Inc $MOH**
- Source: MarketBeat | 20260104T102126 | Neutral | Relevance: 100%
- Merit Financial Group LLC significantly increased its stake in Molina Healthcare (NYSE:MOH) by 289.3% in Q3, adding 8,721 shares to hold a total of 11,735 shares valued at approximately $2.246 million. Despite Molina reporting a Q3 EPS of $1.84, missing consensus estimates, and setting FY2025 guidance at $14.00 EPS, the company maintains a consensus Hold rating and a $196.33 price target from analysts. Other institutional investors also adjusted their positions in MOH during the same period.

**5. Molina Healthcare (MOH) director receives 317-share equity grant for Q1 2026**
- Source: Stock Titan | 20260103T020838 | Neutral | Relevance: 100%
- A Molina Healthcare director, Richard M. Schapiro, received an equity grant of 317 common shares on January 1, 2026, as part of the company's 2025 Equity Incentive Plan for his services. This quarterly award, valued at $55,000, was determined by the previous day's closing stock price of $173.54. Following this transaction, the director directly holds 11,669 shares of Molina Healthcare common stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $164 | $144 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | main | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.1%)
- Capital World Invest: 9.5% (-2.0%)
- Blackrock Inc.: 8.4% (-3.9%)
- Price (T.Rowe) Assoc: 6.5% (+58.8%)
- AQR Capital Manageme: 5.4% (+217.0%)

### Key Risks

1. Valuation risk: PEG 2.7x with declining EPS estimates leaves no margin for error.
2. Elevated short interest (9.4%): bears positioning against stock.
3. Long-term trend broken: trading 18.1% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +6.5% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 2.69 signals overvaluation risk, limited margin of safety. Analyst sentiment positive (1 raises, avg +14%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.9B |
| Beta | 0.49 |
| 52W Range | $133.40 - $359.97 |
| Short Interest | 9.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.69 |
| Forward P/E | 14.6 |
| Current P/E | 13.1 |
| YoY Growth | -10.1% |
| EPS Direction | FALLING |

### Technicals

MRS_20 strengthening from 4.0% to 10.5% (+6.5% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (10.5% > 10.0%), caution on chasing. MRS_5 at 4.7% confirms short-term momentum alignment. AM_20 at 10.7% shows strong absolute momentum above own 20MA. Outperforming sector by 10.0pp, stock-specific strength. Below SMA200 (0.82x), long-term trend not supportive. MACD histogram positive (1.88), confirming momentum. RSI overbought at 77, risk of mean reversion. OFD pattern: +SUN (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 10.51% (CS: 97) | Strong |
| RSI_14 | 77.4 | Overbought |
| MACD Histogram | 1.88 | Bullish |
| vs SMA20 | 1.107x | Above |
| vs SMA50 | 1.181x | Above |
| vs SMA200 | 0.819x | Below |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $182.86
- **Stop Loss:** $171.36 (6.3% risk)
- **Target:** $194.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 74
- **Position Value:** $13,531.64
- **Portfolio %:** 13.53%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-04 (Est: $0.64)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.89 | $1.84 | -52.7% |
| 2025Q2 | $5.53 | $5.48 | -0.9% |
| 2025Q1 | $5.96 | $6.08 | +2.0% |
| 2024Q4 | $5.88 | $5.05 | -14.1% |

---
*RULE-based L3 | 2026-01-07 09:36 | MRS_20*